BioSpace News Archive

Alexion Pharmaceuticals announced that management will present at the 38th Annual J.P Morgan Healthcare Conference in San Francisco, CA on Tuesday, January 14th, 2019 at 7:30 a.m, PT. A breakout question and answer session will immediately follow the formal presentation.

TherapeuticsMD, Inc. announced that the company will participate in the 38th Annual J.P. Morgan Healthcare Conference in San Francisco. Chief Executive Officer Robert G. Finizio will provide an overview of the company at the conference.

Eagle Pharmaceuticals, Inc. announced a new research agreement with NorthShore University HealthSystem in Evanston, IL, focused on studying Eagle’s RYANODEX® for traumatic brain injury in animal models.

BioCryst Pharmaceuticals, Inc. announced that the compensation committee of BioCryst’s board of directors granted two newly-hired employees options to purchase an aggregate of 20,000 shares of BioCryst common stock on December 31, 2019 as inducements material to each employee entering into employment with BioCryst.

Myriad Genetics, Inc. (NASDAQ: MYGN, “Myriad” or the “Company”), a global leader in molecular diagnostics and precision medicine, announced that a new analysis of the GUIDED1 clinical trial using the 6-item Hamilton Depression Rating Scale (HAM-D6) was published online in BMC Psychiatry

Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced the appointment of Katina Dorton to the Company’s board of directors and as chair of the audit committee.

FibroGen, Inc. announced that its Board of Directors unanimously appointed Enrique Conterno as the company’s Chief Executive Officer and a member of the Board of Directors.

Precision BioSciences, Inc. (Nasdaq: DTIL), a genome editing company dedicated to improving life through the application of its pioneering, proprietary ARCUS® platform, today announced that Matt Kane, co-founder and CEO, will present at the 38th Annual J.P. Morgan Healthcare Conference

HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform, today announced that HOOKIPA has made strong progress in its collaboration with Gilead

Includes leading protein conjugation technologies and industry brands Lightning-Link® and CaptSure™